University of Rochester

University of Nebraska

Stephen Dewhurst

Harris A Gelbard

Torsten R Wiemann

Val S Goodfellow

Colin J Loweth

John J Treanor

Andrew Cox

Shohei Koide

Howard E Gendelman

Howard J Federoff

Satheesh Babu Ravula

Mark A Sullivan

William J Bowers

Akiko Koide

Baek Kim

John G Frelinger

Joseph D Rosenblatt

Khaled A Tolba

Michelle Miller

Julie Richards

Thomas G Evans

Richard A Willis

John Treanor

Colin Loweth

Thomas J Evans

Peter K Hocknell

Torsten Wiemann

Disclosed are compositions and methods for related to mutant influenza viruses with increased fidelity.

Methods and compositions related to increasing the fidelity of influenza A virus for vaccine development

Disclosed are methods for treating an individual infected with a retrovirus that comprise administering to the individual effective amounts of a mixed lineage kinase inhibitor and antiretroviral drug. In further aspects, disclosed are methods for treating an individual infected with a retrovirus that comprises administering an antiretroviral drug formulated into a crystalline nanoparticle comprising a surfactant, and a MLK inhibitor. Still further disclosed are methods for treating an individual infected with a retrovirus that comprises administering a composition comprising both an antiretroviral and MLK inhibitor formulated into a crystalline nanoparticle, which comprises a surfactant. Still further disclosed are compositions that comprise an antiretroviral drug, a MLK inhibitor, and a surfactant, wherein the composition is a crystalline nanoparticle. Compostions comprising MLK inhibitors with other drugs in nanoparticulate form, and methods of there use, are also disclosed.

Mixed lineage kinase inhibitors for HIV/AIDS therapies

Provided herein are attenuated influenza viruses and methods of making attenuated influenza viruses.

Attenuated influenza vaccines and uses thereof

Provided are compounds having an inhibitory effect on Mixed Lineage Kinases. The compounds include substituted pyrrolo[2,3-b]pyridines having Formula IX  Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment neuropsychiatric disorders which comprise the inhibition of Mixed Lineage Kinases.

Substituted pyrrolo[2,3-b]pyridines as MLK inhibitors

Provided are compounds having an inhibitory effect on Mixed Lineage Kinases. The compounds include substituted pyrrolo [b]pyridines having Formula IX  Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment of neuropsychiatric disorders which comprise the inhibition of Mixed Lineage Kinases.

Substituted pyrrolo[2,3-B]pyridines as MLK inhibitors

The present invention relates to an anti-idiotypic polypeptide scaffold that includes two or more peptide sequences that mimic a discontinuous epitope of a pathogen that is recognized by or induces formation of a broadly neutralizing antibody. Using a fibronectin FNfn10 scaffold bearing two or more modified discontinuous loops, scaffolds that recognize broadly neutralizing antibodies in vitro and from patient serum have been identified. These scaffolds should induce an immune response or mobilize germline specificities to initiate their affinity maturation.

Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies

Provided are compounds having an inhibitory effect on Mixed Lineage Kinases, having a structural Formula, Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment of neuropsychiatric disorders which comprise the inhibition of Mixed Lineage Kinases.

Provided are compounds having an inhibitory effect on kinases including Mixed Lineage Kinases. Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions that are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment of neuropsychiatric disorders that comprise the inhibition of Mixed Lineage Kinases.

Bicyclic heteroaryl kinase inhibitors and methods of use

Disclosed herein are modified phage comprising a fusion protein located on the surface of the phage wherein the fusion protein comprises a surface protein and a post-translationally modified protein. Also disclosed are methods of making and using modified phage comprising post-translationally modified proteins located on the surface of the phage.

Modified phage for displaying post-translationally modified proteins and uses thereof

The invention features new helper virus-free methods for making herpesvirus amplicon particles that can be used in immunotherapies, including those for treating any number of infectious diseases and cancers (including chronic lymphocytic leukemia, other cancers in which blood cells become malignant, lymphomas (e.g. Hodgkin's lymphoma or non-Hodgkin's type lymphomas). Described herein are methods of making helper virus-free HSV amplicon particles; cells that contain those particles (e.g., packaging cell lines or patients' cells, infected in vivo or ex vivo); particles produced according to those methods; and methods of treating a patient with an hf-HSV particle made according to those methods.

Helper virus-free herpesvirus amplicon particles and uses thereof

The present invention relates to a polypeptide monobody which includes a modified acid sequence and renders the polypeptide monobody able to bind selectively to &#x3b1;&#x3bd;&#x3b2;3 integrin. Fusion proteins and conjugates which include the polypeptide monobody, as well as compositions containing the polypeptide monobody, fusion proteins, or conjugates are also disclosed. Uses thereof include: treating or preventing an &#x3b1;&#x3bd;&#x3b2;3 integrin-mediated disease or disorder, inhibiting &#x3b1;&#x3bd;&#x3b2;3 integrin activity, treating a cancerous or precancerous condition, imaging tissues using positron emission tomography or magnetic resonance imaging, assessing the metastatic characteristics of a tumor, and delivering DNA to a cell.

Growing community of inventors

Rochester, NY, United States of America

Stephen Dewhurst